CY1112783T1 - Συμπλοκα φορτισμενης λιποπρωτεϊνης και χρησεις αυτων - Google Patents
Συμπλοκα φορτισμενης λιποπρωτεϊνης και χρησεις αυτωνInfo
- Publication number
- CY1112783T1 CY1112783T1 CY20121100451T CY121100451T CY1112783T1 CY 1112783 T1 CY1112783 T1 CY 1112783T1 CY 20121100451 T CY20121100451 T CY 20121100451T CY 121100451 T CY121100451 T CY 121100451T CY 1112783 T1 CY1112783 T1 CY 1112783T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- charged lipoprotein
- complexes
- charged
- lipoprotein
- Prior art date
Links
- 102000004895 Lipoproteins Human genes 0.000 title abstract 2
- 108090001030 Lipoproteins Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Endocrinology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66518005P | 2005-03-24 | 2005-03-24 | |
| EP06727346A EP1871341B8 (en) | 2005-03-24 | 2006-03-23 | Charged lipoprotein complexes and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112783T1 true CY1112783T1 (el) | 2016-02-10 |
Family
ID=36659702
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100451T CY1112783T1 (el) | 2005-03-24 | 2012-05-15 | Συμπλοκα φορτισμενης λιποπρωτεϊνης και χρησεις αυτων |
| CY20141100810T CY1115613T1 (el) | 2005-03-24 | 2014-10-08 | Συμπλοκα φορτισμενης λιποπρωτεϊνης και χρησεις αυτων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100810T CY1115613T1 (el) | 2005-03-24 | 2014-10-08 | Συμπλοκα φορτισμενης λιποπρωτεϊνης και χρησεις αυτων |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US8206750B2 (enExample) |
| EP (3) | EP2327396A3 (enExample) |
| JP (2) | JP5317691B2 (enExample) |
| KR (4) | KR20160077225A (enExample) |
| CN (2) | CN103182069B (enExample) |
| AT (1) | ATE547094T1 (enExample) |
| AU (1) | AU2006226045B2 (enExample) |
| BR (1) | BRPI0607728A2 (enExample) |
| CA (1) | CA2602024C (enExample) |
| CY (2) | CY1112783T1 (enExample) |
| DK (2) | DK1871341T3 (enExample) |
| ES (2) | ES2509216T3 (enExample) |
| IL (3) | IL186169A (enExample) |
| MX (1) | MX2007011851A (enExample) |
| NZ (2) | NZ562346A (enExample) |
| PL (2) | PL1871341T3 (enExample) |
| PT (2) | PT2289490E (enExample) |
| SI (2) | SI1871341T1 (enExample) |
| WO (1) | WO2006100567A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2006125304A1 (en) * | 2005-05-25 | 2006-11-30 | Liponex, Inc. | Pharmaceutical compositions for treating or preventing coronary artery disease |
| WO2007137400A1 (en) * | 2006-06-01 | 2007-12-06 | Institut De Cardiologie De Montreal | Method and compound for the treatment of valvular stenosis |
| US7985728B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US9173890B2 (en) * | 2007-09-20 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US8101565B2 (en) | 2007-09-20 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Sustained release of Apo A-I mimetic peptides and methods of treatment |
| US7985727B1 (en) | 2007-09-20 | 2011-07-26 | Abbott Cardiovascular Systems Inc. | Apo A-I mimetic peptides and methods of treatment |
| US8044021B2 (en) * | 2007-09-20 | 2011-10-25 | Abbott Cardiovascular Systems Inc. | Sustained release of apo A-I mimetic peptides and methods of treatment |
| US8734853B2 (en) | 2008-11-17 | 2014-05-27 | University Of North Texas Health Science Center At Fort Worth | HDL particles for delivery of nucleic acids |
| US20120021982A1 (en) * | 2009-01-23 | 2012-01-26 | Jean-Claude Tardif | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction |
| SI2396017T1 (sl) | 2009-02-16 | 2015-12-31 | Cerenis Therapeutics Holding Sa | Mimika apolipoproteina A-1 |
| EP2453876A1 (en) | 2009-07-16 | 2012-05-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Hdl comprising a therapeutic agent and use in therapy |
| US10525152B2 (en) * | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| US10894098B2 (en) | 2012-04-09 | 2021-01-19 | Signablok, Inc. | Methods and compositions for targeted imaging |
| US12419839B2 (en) | 2009-10-09 | 2025-09-23 | Signablok, Inc. | Methods and compositions for targeted delivery of protein fragments |
| US20110152112A1 (en) * | 2009-12-23 | 2011-06-23 | Artery Therapeutics, Inc. | Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases |
| AR082644A1 (es) | 2010-08-30 | 2012-12-19 | Hoffmann La Roche | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contiene y utilizacion de la misma relacionado con el metabolismo de los lipidos y las enfermedades cardiovasculares |
| RS58275B1 (sr) * | 2011-02-07 | 2019-03-29 | Cerenis Therapeutics Holding Sa | Lipoproteinski kompleksi i njihova proizvodnja i upotrebe |
| AU2015271986B2 (en) * | 2011-02-07 | 2018-02-22 | Cerenis Therapeutics Holding Sa | Lipoprotein complexes and manufacturing and uses thereof |
| JP2014509646A (ja) * | 2011-03-25 | 2014-04-21 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | ペグ化ヒトｈｄｌ粒子およびその製造方法 |
| CA2838070A1 (en) | 2011-08-25 | 2013-02-28 | F. Hoffmann-La Roche Ag | Shortened tetranectin-apolipoprotein a-i fusion protein, a lipid particle containing it, and uses thereof |
| WO2014160237A2 (en) * | 2013-03-14 | 2014-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of prognosing preeclampsia |
| US9708354B2 (en) | 2013-03-15 | 2017-07-18 | Cerenis Therapeutics Holding Sa | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins |
| KR20150132188A (ko) | 2013-03-15 | 2015-11-25 | 세레니스 쎄라퓨틱스 홀딩 에스에이 | 스핑고미엘린 및 디히드로스핑고미엘린의 합성 방법 |
| EP2853259A1 (en) * | 2013-09-30 | 2015-04-01 | Université Pierre et Marie Curie (Paris 6) | Reconstituted high density lipoproteins composition and uses thereof |
| KR20170003611A (ko) | 2014-05-02 | 2017-01-09 | 세레니스 쎄라퓨틱스 홀딩 에스에이 | Ｈｄｌ 요법 마커 |
| US20160346221A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
| US20170165200A1 (en) * | 2015-11-20 | 2017-06-15 | University Of North Texas Health Science Center | Composition of lipid-based nanoparticles for small molecules and macromolecules |
| US20190046608A1 (en) * | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding Sa | Apomers |
| EP3668600B1 (en) * | 2017-08-10 | 2024-05-15 | Abionyx Pharma SA | Cargomers |
| CN110151972A (zh) * | 2018-02-11 | 2019-08-23 | 中国中医科学院中医基础理论研究所 | 基于多肽的重组高密度脂蛋白前体及其制备方法与应用 |
| US12220462B1 (en) | 2018-02-13 | 2025-02-11 | Abionyx Pharma Sa | Complexes for delivery of cyclic dinucleotides |
| DE202019003092U1 (de) * | 2019-07-24 | 2020-01-17 | Ruth-Maria Korth | Test zur Bestimmung von Proteophospholipiden und FIDA-Formeln zur Bestimmung von Schutzfaktoren , die mit Substraten auszugleichen sind |
| CA3177735A1 (en) | 2020-04-16 | 2021-10-21 | Abionyx Pharma Sa | Cer-001 therapy for treating kidney disease |
| CN115427064A (zh) | 2020-04-16 | 2022-12-02 | 阿比奥尼克斯制药公司 | 使用基于脂质结合蛋白的复合物治疗急性病况的方法 |
| IL301769A (en) | 2020-10-01 | 2023-05-01 | Abionyx Pharma Sa | Methods for treating eye diseases using lipid binding protein-based complexes |
| MX2023012223A (es) | 2021-04-15 | 2023-10-26 | Abionyx Pharma Sa | Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos. |
| KR102531293B1 (ko) * | 2021-12-06 | 2023-05-16 | (주) 멥스젠 | 신규한 재구축 고밀도 지단백 나노입자 |
| KR20240167701A (ko) | 2022-04-06 | 2024-11-27 | 아비오닉스 파마 에스에이 | 지질 결합 단백질-기반 복합체를 사용하여 안질환을 치료하는 방법 |
| US20250255931A1 (en) | 2022-04-06 | 2025-08-14 | Abionyx Pharma Sa | Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes |
| US20250352613A1 (en) | 2022-06-10 | 2025-11-20 | Stanislas FAGUER | Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes |
| WO2023237935A2 (en) | 2022-06-10 | 2023-12-14 | Abionyx Pharma Sa | Methods for treating acute conditions using lipid binding protein-based complexes |
| WO2024150064A1 (en) | 2023-01-13 | 2024-07-18 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
| WO2025093929A1 (en) | 2023-10-31 | 2025-05-08 | Abionyx Pharma Sa | Lipid binding protein molecule therapy |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5052123A (enExample) * | 1973-01-18 | 1975-05-09 | ||
| US4466958A (en) * | 1981-03-18 | 1984-08-21 | Morrison L M | Food supplement |
| JPS59164553A (ja) * | 1983-03-08 | 1984-09-17 | Fuji Photo Film Co Ltd | カラ−写真感光材料 |
| DE3417696A1 (de) * | 1984-05-12 | 1985-11-14 | Robert Bosch Gmbh, 7000 Stuttgart | Vorrichtung zum volumetrischen abmessen und abfuellen von fluessigkeitsmengen |
| US5128318A (en) * | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| GB8712540D0 (en) | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
| US5231090A (en) * | 1990-07-30 | 1993-07-27 | University Of Miami | Treatment for hypercholesterolemia |
| US5220043A (en) | 1991-03-21 | 1993-06-15 | Ohio University | Synthesis of D-erythro-sphingomyelins |
| SE9103701D0 (sv) | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| WO1995008986A1 (en) | 1993-09-27 | 1995-04-06 | Smithkline Beecham Corporation | Camptothecin formulations |
| US5746223A (en) * | 1996-10-11 | 1998-05-05 | Williams; Kevin Jon | Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis |
| JP3754072B2 (ja) | 1994-03-22 | 2006-03-08 | リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド | 摂食抑制ペプチド |
| US5932536A (en) | 1994-06-14 | 1999-08-03 | The Rockefeller University | Compositions for neutralization of lipopolysaccharides |
| US5948756A (en) * | 1995-08-31 | 1999-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Therapeutic lipoprotein compositions |
| IL120005A (en) * | 1997-01-14 | 2000-08-31 | Ramot University Authority Of | Pharmaceutical compositions for the treatment of the eye |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6287590B1 (en) * | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
| US6017882A (en) * | 1997-10-23 | 2000-01-25 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| GB9919713D0 (en) | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| US6514523B1 (en) * | 2000-02-14 | 2003-02-04 | Ottawa Heart Institute Research Corporation | Carrier particles for drug delivery and process for preparation |
| CA2455170A1 (en) * | 2000-07-31 | 2002-02-07 | Ottawa Heart Institute Research Corporation | Charged phospholipid compositions and methods for their use |
| US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
| US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
| US7148197B2 (en) | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
| US7217785B2 (en) | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| US20040266660A1 (en) | 2001-08-20 | 2004-12-30 | Alphonse Hubsch | Hdl for the treatment of stroke and other ischemic conditions |
| AUPR798901A0 (en) | 2001-09-28 | 2001-10-25 | Medvet Science Pty. Ltd. | Spheroidal hdl particles with a defined phospholipid composition |
| PL372925A1 (en) | 2001-09-28 | 2005-08-08 | Esperion Therapeutics Inc. | Prevention and treatment of restenosis by local administration of drug |
| US7223726B2 (en) | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
| FR2836043B1 (fr) | 2002-02-15 | 2004-06-04 | Inst Nat Sante Rech Med | Vesicules lipidiques, preparation et utilisations |
| BR0310100A (pt) * | 2002-05-17 | 2007-04-27 | Esperion Therapeutics Inc | métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto |
| MXPA04011312A (es) * | 2002-05-17 | 2005-02-14 | Esperion Therapeutics Inc | Metodo para el tratamiento de desordenes dislipidemicos. |
| JP2006508045A (ja) * | 2002-07-30 | 2006-03-09 | エスペリオン セラピューティクス，インコーポレイテッド | ヒト以外の動物のアポリポプロテインａ−ｉタンパク質の使用方法 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2007137400A1 (en) * | 2006-06-01 | 2007-12-06 | Institut De Cardiologie De Montreal | Method and compound for the treatment of valvular stenosis |
| RS58275B1 (sr) | 2011-02-07 | 2019-03-29 | Cerenis Therapeutics Holding Sa | Lipoproteinski kompleksi i njihova proizvodnja i upotrebe |
-
2006
- 2006-03-22 US US11/388,135 patent/US8206750B2/en active Active
- 2006-03-23 ES ES10010660.8T patent/ES2509216T3/es active Active
- 2006-03-23 PT PT100106608T patent/PT2289490E/pt unknown
- 2006-03-23 AU AU2006226045A patent/AU2006226045B2/en active Active
- 2006-03-23 MX MX2007011851A patent/MX2007011851A/es active IP Right Grant
- 2006-03-23 CA CA2602024A patent/CA2602024C/en active Active
- 2006-03-23 AT AT06727346T patent/ATE547094T1/de active
- 2006-03-23 EP EP10010652A patent/EP2327396A3/en not_active Withdrawn
- 2006-03-23 CN CN201210518647.4A patent/CN103182069B/zh active Active
- 2006-03-23 ES ES06727346T patent/ES2382958T3/es active Active
- 2006-03-23 WO PCT/IB2006/000635 patent/WO2006100567A1/en not_active Ceased
- 2006-03-23 CN CN2006800151378A patent/CN101170994B/zh active Active
- 2006-03-23 PT PT06727346T patent/PT1871341E/pt unknown
- 2006-03-23 DK DK06727346.6T patent/DK1871341T3/da active
- 2006-03-23 JP JP2008502504A patent/JP5317691B2/ja active Active
- 2006-03-23 EP EP06727346A patent/EP1871341B8/en active Active
- 2006-03-23 SI SI200631327T patent/SI1871341T1/sl unknown
- 2006-03-23 EP EP10010660.8A patent/EP2289490B1/en active Active
- 2006-03-23 BR BRPI0607728-5A patent/BRPI0607728A2/pt active Search and Examination
- 2006-03-23 PL PL06727346T patent/PL1871341T3/pl unknown
- 2006-03-23 KR KR1020167016313A patent/KR20160077225A/ko not_active Abandoned
- 2006-03-23 KR KR1020147015584A patent/KR101769191B1/ko active Active
- 2006-03-23 DK DK10010660.8T patent/DK2289490T3/da active
- 2006-03-23 NZ NZ562346A patent/NZ562346A/xx unknown
- 2006-03-23 NZ NZ582888A patent/NZ582888A/en unknown
- 2006-03-23 PL PL10010660T patent/PL2289490T3/pl unknown
- 2006-03-23 KR KR1020187005474A patent/KR20180026548A/ko not_active Ceased
- 2006-03-23 SI SI200631830T patent/SI2289490T1/sl unknown
-
2007
- 2007-09-23 IL IL186169A patent/IL186169A/en active IP Right Grant
- 2007-09-24 IL IL186245A patent/IL186245A0/en unknown
- 2007-10-23 KR KR1020077024377A patent/KR101475419B1/ko active Active
-
2012
- 2012-03-21 JP JP2012063853A patent/JP5542166B2/ja active Active
- 2012-05-03 US US13/463,582 patent/US8617615B2/en active Active
- 2012-05-10 IL IL219721A patent/IL219721A/en active IP Right Grant
- 2012-05-15 CY CY20121100451T patent/CY1112783T1/el unknown
-
2013
- 2013-11-20 US US14/085,685 patent/US9567388B2/en active Active
-
2014
- 2014-10-08 CY CY20141100810T patent/CY1115613T1/el unknown
-
2017
- 2017-01-04 US US15/398,219 patent/US11801282B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115613T1 (el) | Συμπλοκα φορτισμενης λιποπρωτεϊνης και χρησεις αυτων | |
| CR9672A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| BRPI0607379B8 (pt) | composição farmacêutica de efeito analgésico | |
| CY2014026I1 (el) | Συνθεσεις και χρησεις για θεραπεια σκληρυνσης κατα πλακας | |
| ECSP056064A (es) | Compuestos de benzopirano utiles para tratar estados inflamatorios | |
| ATE539079T1 (de) | Imidazochinoxalinverbindungen als immunmodulatoren | |
| EA201001356A1 (ru) | Новые замещенные имидазохинолины | |
| CY1109737T1 (el) | Νεα μεθοδος συνθεσης του (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης | |
| DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
| CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
| CR9947A (es) | Compuestos de pirimidinil benzotiofeno | |
| ATE511845T1 (de) | Verwendung von isothicyanat-derviaten als myelom- bekämpfende wirkstoffe | |
| CY1115094T1 (el) | Νεα μεθοδος για την συνθεση (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στην συνθεση αγομελατινης | |
| EA201170344A1 (ru) | Азаиндольные ингибиторы iap | |
| ATE476193T1 (de) | Immunstimulatorisches verfahren | |
| CR8696A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias | |
| HN2010000330A (es) | DERIVADOS DE INDOL-2-ONA DISUSTITUIDOS EN 3 y SU PREPARACION | |
| CY1110891T1 (el) | Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη | |
| CY1111081T1 (el) | Νεα μεθοδος συνθεσης του (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγκομελατινης | |
| ATE527996T1 (de) | Medizinische verwendung von 3-(2,2,2- trimethylhydrazinium)propionat-orotat | |
| CY1115131T1 (el) | Παραγωγα αλκυλ φωσφολιπιδιων με μειωμενη κυτταροτοξικοτητα και χρησεις εξ αυτων |